Informed Consent for Assisted Reproduction:
Oocyte Recipient, In Vitro Fertilization, Intracytoplasmic Sperm Injection, Assisted Hatching, Embryo Cryopreservation

Please place your initials below to indicate which components of IVF treatment you agree to undertake in your upcoming treatment cycle. Also, initial each page to indicate that you have read and understand the information provided. If you do not understand the information provided, please speak with your treating provider. There are a few locations within the consent form where you are being asked to make a decision. Please initial your choice and sign where requested.

Chosen Elements of Treatment:

<table>
<thead>
<tr>
<th>Signatures</th>
<th>Option</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient:</td>
<td>In Vitro Fertilization</td>
</tr>
<tr>
<td>Spouse/Partner:</td>
<td></td>
</tr>
<tr>
<td>Date:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Intracytoplasmic Sperm Injection (ICSI)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Embryo Cryopreservation</td>
</tr>
<tr>
<td></td>
<td>(requires completion of Disposition of Embryos statement)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Decline Embryo Cryopreservation</td>
</tr>
<tr>
<td></td>
<td>(Does NOT require completion of Disposition of Embryos statement)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Provider / Witness: Date:
OVERVIEW

In Vitro Fertilization (IVF) has become an established treatment for many forms of infertility. The main goal of IVF is to allow a patient the opportunity to become pregnant using her own eggs or donor eggs and sperm from her partner or from a donor. This is an elective procedure designed to result in the patient’s pregnancy when other treatments have failed or are not appropriate.

This consent reviews the IVF process from start to finish, including the risks that this treatment might pose to you and your offspring. While best efforts have been made to disclose all known risks, there may be risks of IVF that are not yet clarified or even suspected at the time of this writing.

An IVF/Recipient cycle typically includes the following steps or procedures:
- Medications to grow multiple eggs (to yourself or an egg donor)
- Retrieval of eggs from the ovary or ovaries
- Insemination of eggs with sperm
- Culture of any resulting fertilized eggs (embryos)
- Uterine lining preparation with medication
- Placement (“transfer”) of one or more embryo(s) into the uterus
- Support of the uterine lining with hormones to permit and sustain pregnancy

In certain cases, these additional procedures can be employed:
- Intracytoplasmic sperm injection (ICSI) to increase the chance for fertilization
- Assisted hatching of embryos to potentially increase the chance of embryo attachment (“implantation”)
- Embryo Cryopreservation (freezing)
- In Vitro Maturation (IVM) of oocytes to reduce risk of hyperstimulation and/or OHSS

Screening

Before you can undergo your ART procedure, you and your partner will need to have testing to assist us in ensuring your safety during your treatment and anticipated pregnancy. Some of these tests will look for infections that could endanger a pregnancy or contaminate the embryology laboratory and endanger other pre-implantation embryos (to be referred to as embryos). We will test you for sexually transmitted disease, hepatitis, and HIV (the virus that causes AIDS). If we find evidence of any type of infection, we will discuss the results of your test with you and, if needed, refer you for treatment or treat you ourselves.

In addition to infectious disease screening, we will ask you to have tests that we would recommend for any women anticipating pregnancy or infertility treatments. These tests include blood typing and Rh, rubella titer, complete blood count (CBC), blood chemistries (SMAC), and a Pap smear. We require all of these screening procedures before your first cycle of treatment. For subsequent cycles you may need to repeat a few of these tests. If more than a year has gone by since your first cycle, we will require you to repeat your screening tests.

Your embryos will have a better chance of implanting if the inside of your uterus is normal. Studies that will help us to confirm that your uterus is normal are: hysterosalpingogram (HSG), hysteroscopy or hysterosonogram (HSN).

Your male partner (if applicable) must have a semen analysis performed by our laboratory within six months of the start of (each of) your treatment cycle(s).
You (or your chosen egg donor) will have baseline blood tests and possibly an ultrasound and anti mullerian hormone (AMH) to assess ovarian reserve. These are tests of follicle-stimulating hormone (FSH) and estradiol (E2) that we perform early in your menstrual cycle, around the third day of the cycle. Many reference laboratories perform FSH and E2 tests, but each lab reports their results differently. Therefore we ask that you have your baseline tests performed at Delaware Valley Institute of Fertility & Genetics, if possible. You will have the baseline tests repeated immediately before you start your treatment cycle.
In addition to FSH and estradiol, your pretreatment baseline tests may also include a progesterone (PGN),
Luteinizing Hormone (LH) and pregnancy test. If your baseline tests are abnormal, we may ask you to speak with your provider to discuss the potential ramifications of this upon your treatment success.

Financial consultation should be completed prior to baseline evaluation. If you have to pay “out of pocket” the cost of an entire ART cycle in 2010 will be in the neighborhood of $10,000 - $20,000. This approximates all costs including medication and possible cryopreservation. Please speak to our financial counselor for details about your financial obligations to the center and for a review of what benefits are available under your insurance plan.

**Consults with other health professionals**

We recommend that each couple that plans to have ART procedures at Delaware Valley Institute of Fertility & Genetics undergo psychological screening with our affiliated psychological counselor. Couples who plan to use sperm or eggs that are not their own are required to see the counselor. In addition, any couple with a history of substance abuse for either partner must see the psychological counselor.

ART procedures are very stressful. We view this pre-cycle counseling visit as an opportunity to prepare you for the stresses of your cycle. Couples, who are identified by the counselor as needing further support, will be referred for continued counseling. If you like, you may also have an interview with the counselor after you have concluded treatment.

We will ask some couples anticipating in ART procedures to have genetic screening. The particular genetic screening will differ from couple to couple. If you do need genetic screening, we will offer to refer you to a genetic counselor who will advise you of the risks and benefits of screening.

Pregnancy itself can be a health risk. If you are over the age of 45 or have any significant illness (such as asthma, diabetes, or multiple sclerosis), you must be cleared by your internist and a board-certified perinatologist of your choice before starting your treatment. All women over the age of 45 will require a cardiac stress test. If you have a history of any other significant illness, you will need a consultation with another relevant specialist before starting your treatment.

We require all of these screening procedures before your first cycle of treatment. For subsequent cycles you may need to repeat a few of these tests. If more than a year has gone by since your first cycle, we will require you to repeat all of your screening tests. At the end of screening, you will meet with your Reproductive Endocrinologist to review the results of your tests, discuss plans for your treatment cycle, and give your provider an opportunity to prescribe your medications.

**The Cycle**

**Beginning your Treatment Cycle**

You must have a consultation with our IVF or Third Party Coordinator in order to start a treatment cycle. We will base your cycle schedule on the type of treatment that you plan to have and on the approximate date of your next menstrual cycle. Please call the IVF coordinator at Delaware Valley Institute of Fertility & Genetics to schedule your baseline blood tests on day 2 or 3 of menstrual bleeding (not spotting).

Prescriptions for all medications, based on the orders written by your provider, will be ordered through the appropriate specialty fertility pharmacy. Final payment for your cycle will be due at this time.

Note: At various points in this document, rates are given which reflect what are believed to be U.S. national averages for those employing IVF treatments. These include items such as pregnancy rates, Cesarean delivery rates, and preterm delivery rates. These rates are not meant to indicate the rates of these outcomes within our practice, and are not to be understood as such. Individual practices may have higher or lower pregnancy and delivery rates than these national averages, and also higher or lower risks for certain complications.
Outline of Consent for IVF

A. Technique of In Vitro Fertilization
   1. Core elements and their risk
      a. Medications for uterine preparation
      b. Monitoring
      c. In vitro fertilization and embryo culture
      d. Embryo transfer
      e. Hormonal support of uterine lining
   2. Additional elements and their risk
      a. Intracytoplasmic sperm injection (ICSI)
      b. PolScope
      c. Assisted hatching
      d. Embryo cryopreservation
      e. In Vitro Maturation (IVM)

B. Risks of using donor oocytes
   1. Inaccurate donor history
   2. Genetic disease
   3. Infectious disease
   4. Donor failure
   5. Cancer
   6. Risks of pregnancy

C. Risks to offspring
   1. Overall risks
   2. Birth defects
   3. Risks of a multiple pregnancy

D. Ethical and religious considerations in infertility treatment

E. Psychosocial effects of infertility treatment

F. Alternatives to IVF

G. Reporting Outcomes

H. References

I. Disposition of Embryos Statement

Also note that while this information is believed to be up to date at the time of publication (2010), newer reports may not yet be incorporated into this document.
A. Technique of In Vitro Fertilization

1. Core elements and their risk

   a. Medications for Treatment

   - The success of IVF largely depends on growing multiple eggs at once
   - Injections of the natural hormones FSH and/or LH (gonadotropins) are used for this purpose
   - Additional medications are used to prevent premature ovulation
   - An overly vigorous ovarian response can occur, or conversely an inadequate response

   I/We understand that a variety of medications are available for use to allow adequate preparation of the uterus to sustain a pregnancy and to allow synchronization with the eggs being received from the donor.

   I/We understand that while receiving the medications listed above, the female partner will be closely monitored by the IVF team. I/We understand that this monitoring may include frequent blood drawing, which carries the risk of mild discomfort, bruising at the puncture site or the rare risk of infection. We also understand that ultrasound examinations of the uterus may be performed frequently. These examinations may at times be uncomfortable, but there is no risk presently known to medical science. Occasionally, the female partner may also be asked to collect urine samples for further hormone analysis. I/We understand that if monitoring suggests a low probability of success, that the stimulation cycle may be stopped. I/We understand that we may have the option of using any eggs, which are donated by inseminating them and then freezing any resulting embryos for use in a future cycle.

   - **Lupron**: A GnRH-agonist (leuprolide acetate, Lupron), may be used to suppress the female partner’s cycle. Though leuprolide acetate is an FDA (U.S. Food and Drug Administration) approved medication, it has not been approved for use in IVF, although it has routinely been used in this way for more than 20 years. Potential side effects usually experienced with long-term use include but are not limited to hot flashes, vaginal dryness, bone loss, nausea, vomiting, skin reactions at the injection site, fluid retention, muscle aches, headaches, and depression. No long term or serious side effects are known.

   - **Estradiol**: Estradiol is given to build the endometrial lining of the uterus. It can be given by oral, trans-dermal, intramuscular, or vaginal administration. Side effects of estradiol include nausea, irritation at the application site if given by the trans-dermal route and the risk of blood clots or stroke.

   - **Progesterone**: Progesterone is a hormone normally produced by the ovaries after ovulation. Supplemental progesterone is given to ensure adequate hormonal support of the uterine lining. Progesterone is usually given by injection or by the vaginal route (Endometrin®, Crinone®, Prochieve®, Prometrium®, or pharmacist-compounded suppositories) after egg retrieval.

     Progesterone is often continued for some weeks after a pregnancy has been confirmed. Progesterone has not been associated with an increase in fetal abnormalities. Side effects of progesterone include depression, sleepiness, allergic reaction and if given by intra-muscular injection includes the additional risk of infection or pain at the injection site.

   - **Oral contraceptive pills**: Some treatment protocols include oral contraceptive pills to be taken for 2 to 4 weeks before Lupron injections are started in order to suppress hormone production or
to schedule a cycle. Side effects include unscheduled bleeding, headache, breast tenderness, nausea, swelling and the risk of blood clots or stroke.

- **Other medications**: Antibiotics may be given for a short time during the treatment cycle to reduce the risk of infection associated with embryo transfer. Antibiotic use may be associated with causing a yeast infection, nausea, vomiting, diarrhea, rashes, sensitivity to the sun, and allergic reactions. Other medications such as steroids, heparin, low molecular weight heparin or aspirin may also be included in the treatment protocol.

b. Monitoring

I/We understand that while receiving the medications listed above, the female partner will be closely monitored by the IVF team. I/We understand that this monitoring may include frequent blood drawing, which carries the risk of mild discomfort, bruising at the puncture site or the rare risk of infection. We also understand that ultrasound examinations of the uterus may be performed frequently. These examinations may at times be uncomfortable, but there is no risk presently known to medical science. Occasionally, the female partner may also be asked to collect urine samples for further hormone analysis. I/We understand that if monitoring suggests a low probability of success, that the stimulation cycle may be stopped.

c. **In vitro fertilization and embryo culture**

- Sperm and eggs are placed together in specialized conditions (culture media, controlled temperature, humidity and light) in hopes of fertilization
- Culture medium is designed to permit normal fertilization and early embryo development, but the content of the medium is not standardized.
- Embryo development in the lab helps distinguish embryos with more potential from those with less or none.

After eggs are retrieved, they are transferred to the embryology laboratory where they are kept in conditions that support their needs and growth. The embryos are placed in small dishes or tubes containing "culture medium," which is special fluid developed to support development of the embryo made to resemble that found in the fallopian tube or uterus. The dishes containing the embryos are then placed into incubators, which control the temperature and atmospheric gasses the embryos experience.

Your partner will need to be available on the date of retrieval to provide a semen specimen. If your partner has difficulty producing a specimen by masturbation, please inform us so that we can make arrangements to have him freeze a specimen before you start your cycle. In some cases, sperm will be collected by testicular sperm extraction (TESE). Your male partner’s urologist will perform the TESE procedure. Financial arrangements for TESE must be made with the urologist. There will be a separate billing preparation of the TESE specimen.

A few hours after the eggs are retrieved, sperm are placed in the culture medium with the eggs, or individual sperm are injected into each mature egg in a technique called Intracytoplasmic Sperm Injection (ICSI) (see below). The eggs are then returned to the incubator, where they remain to develop. Periodically over the next few days, the dishes are inspected so the development of the embryos can be assessed.

The following day after eggs have been inseminated or injected with a single sperm (ICSI), they are examined for signs that the process of fertilization is underway. At this stage, normal development is evident by the still single cell having 2 nuclei; this stage is called a zygote. Two days after insemination or
ICSI, normal embryos have divided into about 4 cells. Three days after insemination or ICSI, normally developing embryos contain about 8 cells. Five days after insemination or ICSI, normally developing embryos have developed to the blastocyst stage, which is typified by an embryo that now has 80 or more cells, an inner fluid-filled cavity, and a small cluster of cells called the inner cell mass.

It is important to note that since many eggs and embryos are abnormal, it is expected that not all eggs will fertilize and not all embryos will divide at a normal rate. The chance that a developing embryo will produce a pregnancy is related to whether its development in the lab is normal, but this correlation is not perfect. This means that not all embryos developing at the normal rate are in fact also genetically normal, and not all poorly developing embryos are genetically abnormal. Nonetheless, their visual appearance is the most common and useful guide in the selection of the best embryo(s) for transfer.

In spite of reasonable precautions, any of the following may occur in the lab that would prevent the establishment of a pregnancy:

- Fertilization of the egg(s) may fail to occur.
- One or more eggs may be fertilized abnormally resulting in an abnormal number of chromosomes in the embryo; these abnormal embryos will not be transferred.
- The fertilized eggs may degenerate before dividing into embryos, or adequate embryonic development may fail to occur.
- Bacterial contamination or a laboratory accident may result in loss or damage to some or all of the eggs or embryos.
- Laboratory equipment may fail, and/or extended power losses can occur which could lead to the destruction of eggs, sperm and embryos.
- Other unforeseen circumstances may prevent any step of the procedure to be performed or prevent the establishment of a pregnancy.
- Hurricanes, floods, or other acts of God (including bombings or other terrorist acts) could destroy the laboratory or its contents, including any sperm, eggs, or embryos being stored there.

**d. Embryo transfer**

- After a few days of development, the best appearing embryos are selected for transfer
- The number chosen influences the pregnancy rate and the multiple pregnancy rate
- A woman’s age and the appearance of the developing embryo have the greatest influences on pregnancy outcome
- Embryos are placed in the uterine cavity with a thin tube
- Excess embryos of sufficient quality that are not transferred can be frozen

After a few days of development, one or more embryos are selected for transfer to the uterine cavity. Embryos are placed in the uterine cavity with a thin tube (catheter). Ultrasound guidance may be used to help guide the catheter or confirm placement through the cervix and into the uterine cavity. Although the possibility of a complication from the embryo transfer is very rare, risks include infection and loss of, or damage to the embryos.

The number of embryos transferred influences the pregnancy rate and the multiple pregnancy rate. The age of the woman and the appearance of the developing embryo have the greatest influence on pregnancy outcome and the chance for multiple pregnancy. While it is possible, it is unusual to develop more fetuses than the number of embryos transferred. It is critical to discuss with your provider the number to be transferred before the transfer is done.

In an effort to help curtail the problem of multiple pregnancies (see multiple pregnancies), national guidelines published in 2009 recommend limits on the number of embryos to transfer (see Tables below). These limits should not be viewed as a recommendation on the number of embryos to transfer. These limits differ depending on the developmental stage of the embryos and the quality of the embryos and take into account the patient’s personal history.
In some cases, there will be additional embryos remaining in the lab after the transfer is completed. Depending on their developmental normalcy, it may be possible to freeze them for later use. (See section 2.c for an in-depth discussion of embryo cryopreservation).

e. Hormonal support of the uterine lining

- Successful attachment of embryo(s) to the uterine lining depends on adequate hormonal support
- Progesterone, given by the intramuscular or vaginal route, is routinely given for this purpose

Beginning after the retrieval, and continuing after the transfer, natural progesterone is supplemented either by an intramuscular injection, vaginal suppository, and/or orally in an attempt to increase the chances of successful implantation. The progesterone will be continued until the pregnancy test, and if pregnancy is confirmed, it is continued until the placental production of progesterone becomes dominant (about 8 weeks gestation). During this time, blood levels will be taken and ultrasounds will be performed to confirm an intrauterine pregnancy.
2. **Additional Elements and their risk**

   a. **Intracytoplasmic Sperm Injection (ICSI)**

   - ICSI is used to increase the chance of fertilization when fertilization rates are anticipated to be lower than normal
   - Overall success rates with ICSI are slightly lower than for conventional insemination
   - An increased risk of genetic defects in offspring is reported

The use of ICSI provides an effective treatment for male factor infertility. The negative effects of abnormal semen characteristics and sperm quality on fertilization can be overcome with ICSI if viable sperm are available because the technique bypasses the shell around the egg (zona pellucida) and the egg membrane (oolemma) to deliver the sperm directly into the egg. ICSI involves the direct injection of a single sperm into the interior of an egg using an extremely thin glass needle. ICSI allows couples with male factor infertility to achieve fertilization and live birth rates close to those achieved with in vitro fertilization (IVF) using conventional methods of fertilization in men with normal sperm counts. ICSI can be performed even in men with no sperm in the ejaculate if sperm can be successfully collected from the epididymis or the testis.

Reports on the risk of birth defects associated with ICSI (compared to those associated with conventional fertilization in IVF cycles) have yielded conflicting results. The most comprehensive study conducted thus far, based on data from five-year-old children, has suggested that ICSI is associated with an increased risk of certain major congenital anomalies. However, whether the association is due to the ICSI procedure itself, or to inherent sperm defects, could not be determined because the study did not distinguish between male factor conditions and other causes of infertility. Note that even if there is an increased risk of congenital malformations in children conceived with ICSI, the risk is relatively low (4.2% versus -3% of those conceived naturally). The impact of ICSI on the intellectual and motor development of children conceived via ICSI also has been controversial. An early report suggested that development in such children lagged significantly behind that of children resulting from conventional IVF or those conceived naturally. However, more recent studies from larger groups, using standardized criteria for evaluation, have not detected any differences in the development or the abilities of children born after ICSI, conventional IVF, or natural conception.

The prevalence of sex chromosome abnormalities in children conceived via ICSI is higher than observed in the general IVF population, but the absolute difference between the two groups is small (0.8% to 1.0% in ICSI offspring vs. 0.2% in the general IVF population). The reason for the increased prevalence of chromosomal anomalies observed in ICSI offspring is not clear. Whereas it may result from the ICSI procedure itself, it might also reflect a direct paternal effect. Men with sperm problems (low count, poor motility, and/or abnormal shape) are more likely themselves to have genetic abnormalities and often produce sperm with abnormal chromosomes; the sex chromosomes (X and Y) in the sperm of men with abnormal semen parameters appear especially prone to abnormalities. If sperm with abnormal chromosomes produce pregnancies, these pregnancies will likely carry these same defects. The prevalence of translocations (a re-arrangement of chromosomes that increases the risk of abnormal chromosomes in egg or sperm and can cause miscarriage) of paternal origin and of de novo balanced translocations in ICSI offspring (0.36%) also appears higher than in the general population (0.07%).

Some men are infertile because the tubes connecting the testes to the penis did not form correctly. This condition, called congenital bilateral absence of the vas deferens (CBAVD), can be bypassed by aspirating sperm directly from the testicles or epididymis, and using them in IVF with ICSI to achieve fertilization. However, men with CBAVD are affected with a mild form of cystic fibrosis (CF), and this gene will be passed on to their offspring. All men with CBAVD, as well as their partners, should be tested for CF gene mutations prior to treatment, so that the risk of their offspring having CF can be estimated and appropriate testing performed. It is important to understand that there may be CF gene mutations that are not detectable by current testing and parents who test negative for CF mutations can still have children affected with CF.
Some men have no sperm in their ejaculate because their testes do not produce adequate quantities (non-obstructive azoospermia). This can be due to a number of reasons such as prior radiation, chemotherapy or undescended testicles. In some men, small deletions on their Y chromosome lead to extremely low or absent sperm counts. Testicular biopsy and successful retrieval of viable sperm can be used to fertilize eggs with ICSI. However, any sperm containing a Y chromosomal microdeletion will be transmitted to the offspring. Thus the risk that male offspring might later manifest disorders including infertility is very real. However, men without a detectable deletion by blood testing can generate offspring having a Y chromosome microdeletion, because the chromosomes in the sperm may not be the same as those seen when tested by a blood test.

b. PolScope

In some cases, you may be offered to undergo the ICSI procedure in combination with the PolScope. PolScope technology combines innovations in polarization optics (special lighting and lenses) with novel image-processing software and is used as an add-on technique for the ICSI procedure. When performing ICSI the embryologist holds the egg in place with a thin pipette (similar to a tiny, glass straw). The egg is aligned with the polar body at 12 o’clock. The polar body is the left-over chromosomes (bundles of genes) that have been released from the egg. The polar body is placed at 12 o’clock so that damage to the spindle (the site of the egg’s genes) is minimized. It is done like this as traditional information has suggested that the spindle lies immediately below the polar body.

Use of the polscope has shown that the spindle does not necessarily lie near the polar body. In up to 2/3 of cases, the spindle is not related to the polar body and therefore that spindle may be damaged by the injection needle during the ICSI process. Disruption of the spindle may affect fertilization and how the embryo divides. Use of the polscope allows the embryologist to align the spindle to 12 o’clock, prior to injection of the sperm, avoiding damage to the egg’s genes. It also allows them to identify eggs without spindles, increasing the information available to the patient and their doctor regarding the quality of the eggs produced.

Using the PolScope appears to have a significant effect on the quality of embryos produced during a cycle. Fragmentation of embryos is where there is the appearance of embryo cells falling apart. It is a bad sign and it is also associated with a lower pregnancy rate. With the use of the polscope, the amount of fragmentation is reduced to around 1/3 of embryos generated. Overall this appears to increase the number of quality embryos suitable for use (transfer or cryopreservation). The technique is difficult and time consuming for the embryologists involved however may provide significant advantages for patients undergoing ART.

The use of the PolScope is only a recommendation. However, due to additional fees, it is not mandatory at this time. If you are interested in this treatment, which will require the ICSI procedure, please contact the office administrator for current pricing and notify your IVF coordinator so that the proper procedures may be conducted.

c. Assisted Hatching

- Assisted Hatching involves making a hole in the outer shell (zona pellucida) that surrounds the embryo
- Hatching may make it easier for embryos to escape from the shell that surrounds them.

The cells that make up the early embryo are enclosed within a flexible membrane (shell) called the zona pellucida. During normal development, a portion of this membrane dissolves, allowing the embryonic cells to escape or “hatch” out of the shell. Only upon hatching can the embryonic cells implant within the wall of the uterus to form a pregnancy.

Assisted hatching is the laboratory technique in which an embryologist makes an artificial opening in the shell of the embryo. The hatching is usually performed on the day of transfer, prior to loading the embryo.
into the transfer catheter. The opening can be made by mechanical means (slicing with a needle or burning the shell with a laser) or chemical means by dissolving a small hole in the shell with a dilute acid solution.

We have incorporated artificial or “assisted hatching” into the treatment protocols because we believe it improves implantation rates, and ultimately, live birth rates although definitive evidence of this is lacking.

Risks that may be associated with assisted hatching include damage to the embryo resulting in loss of embryonic cells, or destruction or death of the embryo. Artificial manipulation of the zygote may increase the rates of monozygotic (identical) twinning which are significantly more complicated pregnancies. There may be other risks not yet known.

d. Embryo Cryopreservation

- Freezing of viable embryos not transferred after egg retrieval provides additional chances for pregnancy.
- Frozen embryos do not always survive the process of freezing and thawing.
- Freezing of eggs before fertilization is currently much less successful than freezing of fertilized eggs (embryos).
- Ethical and legal dilemmas can arise when couples separate or divorce; disposition agreements are essential.
- It is the responsibility of each couple with frozen embryos to remain in contact with the clinic on an annual basis.

Freezing (or “cryopreservation”) of embryos is a common procedure. Since multiple eggs (oocytes) are often produced during ovarian stimulation, on occasion there are more embryos available than are considered appropriate for transfer to the uterus. These embryos, if viable, can be frozen for future use. This saves the expense and inconvenience of stimulation to obtain additional eggs in the future. Furthermore, the availability of cryopreservation permits patients to transfer fewer embryos during a fresh cycle, reducing the risk of high-order multiple gestations (triplets or greater). Other possible reasons for cryopreservation of embryos include freezing all embryos in the initial cycle to prevent severe ovarian hyperstimulation syndrome (OHSS), or if a couple were concerned that their future fertility potential might be reduced due to necessary medical treatment (e.g., cancer therapy or surgery). The pregnancy success rates for cryopreserved embryos transferred into the human uterus can vary from practice to practice. Overall pregnancy rates at the national level with frozen embryos are lower than with fresh embryos. This, at least in part, results from the routine selection of the best-looking embryos for fresh transfer, reserving the 'second-best' for freezing. There is some evidence that pregnancy rates are similar when there is no such selection.

**Indications:**
- To reduce the risks of multiple gestation
- To preserve fertility potential in the face of certain necessary medical procedures
- To increase the chance of having one or more pregnancies from a single cycle of ovarian stimulation
- To minimize the medical risk and cost to the patient by decreasing the number of stimulated cycles and egg retrievals
- To temporarily delay pregnancy and decrease the risks of hyperstimulation (OHSS- see below) by freezing all embryos, when this risk is high.

**Risks of embryo cryopreservation:** There are several techniques for embryo cryopreservation, and research is ongoing. Traditional methods include “slow,” graduated freezing in a computerized setting, and “rapid” freezing methods, called “vitrification.” Current techniques deliver a high percentage of viable embryos thawed after cryopreservation, but there can be no certainty that embryos will thaw normally, nor be viable enough to divide and eventually implant in the uterus. Cryopreservation techniques could theoretically be injurious to the embryo. Extensive animal data (through several
generations), and limited human data, do not indicate any likelihood that children born of embryos that have been cryopreserved and thawed will experience greater risk of abnormalities than those born of fresh embryos. However, until very large numbers of children have been born following freezing and thawing of embryos, it is not possible to be certain that the rate of abnormalities is no different from the normal rate.

*If you choose to freeze embryos, you MUST complete and notarize the Disposition for Embryos statement below before freezing. This statement outlines the choices you have with regard to the disposition of embryos in a variety of situations that may arise. You are free to submit a statement at a later time indicating different choices, provided you both agree in writing. It is also incumbent upon you to remain in touch with Delaware Valley Institute of Fertility & Genetics regarding your residence, and to pay for storage charges as they come due.*

**e. In Vitro Maturation**

- In Vitro Maturation (IVM) involves minimal stimulation using gonadotropins and retrieval of the oocytes prior to full maturity followed of oocyte maturation in the laboratory setting
- IVM reduces or eliminates the chances of hyperstimulation in high risk patient groups
- Fewer oocytes are retrieved in IVM procedures when compared to IVF procedures, but have less inherent risks.
- No increase in risk of genetic defects in offspring is reported
- Overall success rates with IVM are slightly lower than for conventional IVF

In Vitro Maturation is very similar to traditional IVF. The IVM patient will undergo exactly the same testing as other IVF patients. However, the amount of medication administered in greatly reduced to a maximum of 3 days. The patient is monitored as described in previous “Monitoring” section. Once the follicles are measured to an appropriate size, usually between 10cm and 11cm, the patient is scheduled for transvaginal oocyte retrieval in the next one or two days. No further injections are given. The reduced medication administration nearly eliminates the patients risk of hyperstimulation.

Oocyte retrieval is similar to that described in “Transvaginal Oocyte Retrieval” in the previous sections, with the same risks and benefits. However, the target follicles are much smaller. As a result, there may be an increase in the procedure time and result in fewer viable oocytes.

Once the oocytes are obtained, they are cultured in maturation media overnight to reach the metaphase-II stage of development. At metaphase-II, the oocytes may be fertilized by the Intracytoplasmic sperm injection methods. Fertilization may be confirmed 18 hours post-injection and be the fertilized zygotes complete the same treatments as traditional IVF procedures.

Reports on the risk of birth defects associated with IVM (compared to those associated with conventional IVF cycles is very reassuring. Follow up studies of over 1000 children conceived by this method report that the obstetric and perinatal outcome was good, and the mean birthweight of the infants was normal.

**B. Risks of Using Donor Oocytes**

1. *Inaccurate donor history*
   Since there is no way to validate a prospective donor’s personal, medical, or family history, donors must be taken at their word. It is possible that the donor may intentionally or inadvertently leave out or falsify important information that has a direct bearing on their suitability as a donor or may impact on children born from the use of their gametes.

2. *Genetic disease*
   It is not possible to test a donor for every type of genetic or hereditary disease. We attempt to screen
donors for common problems based on their ethnic background or family medical history. In most cases, even an apparently negative test cannot completely eliminate the possibility of a donor being a carrier of a genetic disease.

3. **Infectious disease**
   It is not currently possible to rule out the presence of every type of infectious disease. Nor is it possible to rule out the possibility of a known infectious disease. All oocyte donors are screened for infectious disease per FDA guidelines, which include: HIV-1, HIV-2, Hepatitis B, Hepatitis C, Syphilis, Gonorrhea and Chlamydia. There are no reported cases of infections being transmitted by egg donation.

4. **Donor Failure**
   Egg donors must take medication and go through egg retrieval in order to obtain the eggs. It is possible that a donor may fail to complete the necessary steps either intentionally or unintentionally there are necessary to complete the process.

5. **Cancer**
   Many have worried that the use of fertility drugs could lead to an increased risk of cancer—in particular, breast, ovarian, and uterine (including endometrial) cancers. One must be careful in interpreting epidemiological studies of women taking fertility drugs, because all of these cancers are more common in women with infertility, so merely comparing women taking fertility drugs with women in the general population inevitably shows an increased incidence of cancer. When the analysis takes into account the increased cancer risk due to infertility per se, the evidence does not support a relationship between fertility drugs and an increased prevalence of breast or ovarian cancer. More research is required to examine what the long-term impact fertility drugs may be on breast and ovarian cancer prevalence rates. For uterine cancer, the numbers are too small to achieve statistical significance, but it is at least possible that use of fertility drugs may indeed cause some increased risk of uterine cancer.

6. **Risks of Pregnancy**
   Pregnancies that occur with IVF are associated with increased risks of certain conditions (see Table below from the Executive Summary of a National Institute of Child Health and Human Development Workshop held in September 2005, as reported in the journal Obstetrics & Gynecology, vol. 109, no. 4, pages 967-77, 2007). Some of these risks stem from the higher average age of women pregnant by IVF and the fact that the underlying cause of infertility may be the cause of the increased risk of pregnancy complications. There may be additional risks related to the IVF procedure per se, but it is difficult to assign the relative contributions.

<table>
<thead>
<tr>
<th>Potential Risks in Singleton IVF-conceived Pregnancies</th>
<th>Absolute Risk (%) in IVF-conceived Pregnancies</th>
<th>Relative Risk (vs. non IVF-conceived Pregnancies)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-eclampsia</td>
<td>10.3%</td>
<td>1.6 (1.2--2.0)</td>
</tr>
<tr>
<td>Placenta previa</td>
<td>2.4%</td>
<td>2.9 (1.5--5.4)</td>
</tr>
<tr>
<td>Placental abruption</td>
<td>2.2%</td>
<td>2.4 (1.1--5.2)</td>
</tr>
<tr>
<td>Gestational diabetes</td>
<td>6.8%</td>
<td>2.0 (1.4--3.0)</td>
</tr>
<tr>
<td>Cesarean delivery *</td>
<td>26.7%</td>
<td>2.1 (1.7--2.6)</td>
</tr>
</tbody>
</table>

In this table, the Absolute risk is the percent of IVF Pregnancies in which the risk occurred. The Relative Risk is the risk in IVF versus the risk in non-IVF pregnancies; for example, a relative risk of 2.0 indicates that twice as many IVF pregnancies experience this risk as compared to non-IVF pregnancies. The numbers in parentheses (called the “Confidence Interval”) indicate the range in which the actual Relative Risk lies. * Please note that most experts believe the rate of Cesarean delivery to be well above the 26.7% rate quoted here.

Currently more than 30% of IVF pregnancies are twins or higher-order multiple gestations (triplets or greater), and about half of all IVF babies are a result of multiple gestations. Identical twinning occurs in 1.5% to 4.5% of IVF pregnancies. IVF twins deliver on average three weeks earlier and weigh 1,000 gm less than IVF singletons. Of note, IVF twins do as well as spontaneously conceived twins. Triplet (and greater)
Informed Consent for ART

pregnancies deliver before 32 weeks (7 months) in almost half of cases.

Additionally, while embryos are transferred directly into the uterus with IVF, ectopic (tubal, cervical and abdominal) pregnancies as well as abnormal intra-uterine pregnancies have occurred either alone or concurrently with a normal intra-uterine pregnancy. These abnormal pregnancies oftentimes require medical treatments with methotrexate (a weak chemotherapy drug) or surgery to treat the abnormal pregnancy. Side effects of methotrexate include nausea or vomiting, diarrhea, cramping, mouth ulcers, headache, skin rash, sensitivity to the sun and temporary abnormalities in liver function tests. Risks of surgery include the risks of anesthesia, scar tissue formation inside the uterus, infection, bleeding and injury to any internal organs.
C. Risks to Offspring

- IVF babies may be at a slight increased risk for birth defects
- The risk for a multiple pregnancy is significantly higher for patients undergoing IVF, even when only one embryo is transferred
- Multiple pregnancies are the greatest risk for babies following IVF
- Some risk may also stem from the underlying infertile state, or from the IVF techniques, or both

1. Overall risks.

Since the first birth of an IVF baby in 1978, more than 3 million children have been born worldwide following IVF treatments. Numerous studies have been conducted to assess the overall health of IVF children and the majority of studies on the safety of IVF have been reassuring. As more time has passed and the dataset has enlarged, some studies have raised doubts about the equivalence of risks for IVF babies as compared to naturally conceived babies.

A major problem in interpreting the data arises from the fact that comparing a group of infertile couples to a group of normally fertile couples is not the proper comparison to make if one wants to assess the risk that IVF technology engenders. Infertile couples, by definition, do not have normal reproductive function and might be expected to have babies with more abnormalities than a group of normally fertile couples. This said, even if the studies suggesting an increased risk to babies born after IVF prove to be true, the absolute risk of any abnormal outcome appears to be small.

Singletons conceived with IVF tend to be born slightly earlier than naturally conceived babies (39.1 weeks as compared to 39.5 weeks). IVF twins are not born earlier or later than naturally conceived twins. The risk of a singleton IVF conceived baby being born with a birth weight under 5 pounds nine ounces (2500 grams) is 12.5% vs. 7% in naturally conceived singletons.

2. Birth Defects.

The risk of birth defects in the normal population is 2-3%. In IVF babies the birth defect rate may be 2.6-3.9%. The difference is seen predominately in singleton males. Studies to date have not been large enough to prove a link between IVF treatment and specific types of birth defects.

Imprinting Disorders. These are rare disorders having to do with whether a maternal or paternal gene is inappropriately expressed. In two studies approximately 4% of children with the imprinting disorder called Beckwith-Weidemann Syndrome were born after IVF, which is more than expected. A large Danish study however found no increased risk of imprinting disorders in children conceived with the assistance of IVF. Since the incidence of this syndrome in the general population is 1/15,000, even if there is a 2 to 5-fold increase to 2-5/15,000, this absolute risk is very low.

Childhood cancers. Most studies have not reported an increased risk with the exception of retinoblastoma: In one study in the Netherlands, five cases were reported after IVF treatment which is 5 to 7 times more than expected.

Infant Development. In general, studies of long-term developmental outcomes have been reassuring so far; most children are doing well. However, these studies are difficult to do and suffer from limitations. A more recent study with better methodology reports an increased risk of cerebral palsy (3.7 fold) and
developmental delay (4 fold), but most of this stemmed from the prematurity and low birth weight that was a consequence of multiple pregnancy.

### Potential Risks in Singleton IVF Pregnancies

<table>
<thead>
<tr>
<th>Risk</th>
<th>Absolute Risk (%) in IVF Pregnancy</th>
<th>Relative Risk (vs. non-IVF Pregnancies)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preterm birth</td>
<td>11.5%</td>
<td>2.0 (1.7--2.2)</td>
</tr>
<tr>
<td>Low birth weight (&lt; 2500 g)</td>
<td>9.5%</td>
<td>1.8 (1.4--2.2)</td>
</tr>
<tr>
<td>Very low birth weight (&lt; 1500 g)</td>
<td>2.5%</td>
<td>2.7 (2.3--3.1)</td>
</tr>
<tr>
<td>Small for gestational age</td>
<td>14.6%</td>
<td>1.6 (1.3--2.0)</td>
</tr>
<tr>
<td>NICU (intensive care) admission</td>
<td>17.8%</td>
<td>1.6 (1.3--2.0)</td>
</tr>
<tr>
<td>Stillbirth</td>
<td>1.2%</td>
<td>2.6 (1.8--3.6)</td>
</tr>
<tr>
<td>Neonatal mortality</td>
<td>0.6%</td>
<td>2.0 (1.2--3.4)</td>
</tr>
<tr>
<td>Cerebral palsy</td>
<td>0.4%</td>
<td>2.8 (1.3--5.8)</td>
</tr>
<tr>
<td>Genetic risks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-imprinting disorder</td>
<td>0.03%</td>
<td>17.8 (1.8--432.9)</td>
</tr>
<tr>
<td>-major birth defect</td>
<td>4.3%</td>
<td>1.5 (1.3--1.8)</td>
</tr>
<tr>
<td>-of a sex chromosome</td>
<td>0.6%</td>
<td>3.0</td>
</tr>
<tr>
<td>-of another chromosome</td>
<td>0.4%</td>
<td>5.7</td>
</tr>
</tbody>
</table>

In this table, the Absolute risk is the percent of IVF Pregnancies in which the risk occurred. The Relative Risk is the risk in IVF versus the risk in non-IVF pregnancies; for example, a relative risk of 2.0 indicates that twice as many IVF pregnancies experience this risk as compared to non-IVF pregnancies. The numbers in parentheses (called the “Confidence Interval”) indicate the range in which the actual Relative Risk lies.

### 3. Risks of a Multiple Pregnancy

The most important maternal complications associated with multiple gestation are preterm labor and delivery, pre-eclampsia, and gestational diabetes (see prior section on Risks to Woman). Others include gall bladder problems, skin problems, excess weight gain, anemia, excessive nausea and vomiting, and exacerbation of pregnancy-associated gastrointestinal symptoms including reflux and constipation. Chronic back pain, intermittent heartburn, postpartum laxity of the abdominal wall, and umbilical hernias also can occur. Triplets and above increase the risk to the mother of more significant complications including post-partum hemorrhage and transfusion.

Prematurity accounts for most of the excess perinatal morbidity and mortality associated with multiple gestations. Moreover, IVF pregnancies are associated with an increased risk of prematurity, independent of maternal age and fetal numbers. Fetal growth problems and discordant growth among the fetuses also result in perinatal morbidity and mortality. Multifetal pregnancy reduction (where one or more fetuses are selectively terminated) reduces, but does not eliminate, the risk of these complications.

Fetal death rates for singleton, twin, and triplet pregnancies are 4.3 per 1,000, 15.5 per 1,000, and 21 per 1,000, respectively. The death of one or more fetuses in a multiple gestation (vanishing twin) is more common in the first trimester and may be observed in up to 25% of pregnancies after IVF. Loss of a fetus in the first trimester is unlikely to adversely affect the surviving fetus or mother. No excess perinatal or maternal morbidity has been described resulting from a “vanishing” embryo.

Demise of a single fetus in a twin pregnancy after the first trimester is more common when they share a placenta, ranging in incidence from 0.5% to 6.8%, and may cause harm to the remaining fetus.

Multiple fetuses (including twins) that share the same placenta have additional risks. Twin-twin transfusion syndrome in which there is an imbalance of circulation between the fetuses may occur in up to 20% of twins sharing a placenta. Excess or insufficient amniotic fluid may result from twin-to-twin transfusion syndrome. Twins sharing the same placenta have a higher frequency of birth defects compared
to pregnancies having two placentas. Twins sharing the same placenta appear to occur more frequently after blastocyst transfer.

Placenta previa (placenta extends over the cervical opening) and vasa previa (where one or more of the blood vessels extends over the cervical opening) are more common complications in multiple gestations. Abruptio placenta (premature separation of the placenta) also is more common and postpartum hemorrhage may complicate 12% of multifetal deliveries. Consequences of multiple gestations include the major sequelae of prematurity (cerebral palsy, retinopathy of prematurity, and chronic lung disease) as well as those of fetal growth restriction (polycythemia, hypoglycemia, necrotizing enterocolitis). It is unclear to what extent multiple gestations themselves affect neuro-behavioral development in the absence of these complications. Rearing of twins and high-order multiples may generate physical, emotional, and financial stresses, and the incidence of maternal depression and anxiety is increased in women raising multiples. At mid-childhood, prematurely born offspring from multiple gestations have lower IQ scores, and multiple birth children have an increase in behavioral problems compared with singletons. It is not clear to what extent these risks are affected by IVF per se.

The Option of Selective Reduction: Pregnancies that have more than 2 fetuses are considered an adverse outcome of infertility treatment. The greater the number of fetuses within the uterus, the greater is the risk for adverse perinatal and maternal outcomes. Patients with more than twins are faced with the options of continuing the pregnancy with all risks previously described, terminating the entire pregnancy, or reducing the number of fetuses in an effort to decrease the risk of maternal and perinatal morbidity and mortality. Multifetal pregnancy reduction (MFPR) decreases risks associated with preterm delivery, but often creates profound ethical dilemmas. Pregnancy loss is the main risk of MFPR. However, current data suggest that such complications have decreased as experience with the procedure has grown. The risk of loss after MFPR is approximately 1%. In general, the risk of loss after MFPR increases if the number of fetuses at the beginning of the procedure is more than three. While there is little difference between the loss rates observed when the final number of viable fetuses is two or one, the loss rate is higher in pregnancies reduced to triplets, although an increased risk of having a small for gestational age fetus is increased when the starting number is over four. The benefit of MFPR can be documented in triplet and higher-order gestations because reduction prolongs the length of gestation of the surviving fetuses. (This has been demonstrated for triplets; triplets have a 30-35% risk of birth under 32 weeks compared to twins which is 7 to 10%)

D. Ethical and Religious Considerations in Infertility Treatment

Infertility treatment can raise concerns and questions of an ethical or religious nature for some patients. The technique of in vitro fertilization (IVF) involves the creation of human embryos outside the body, and can involve the production of excess embryos and/or ‘high-order’ multiple pregnancy (triplets or more). We encourage patients and their spouses or partners who so desire to consult with trusted members of their religious or ethics community for guidance on their infertility treatment.

E. Psychosocial Effects of Infertility Treatment

A diagnosis of infertility can be a devastating and life-altering event that impacts on many aspects of a patient’s life. Infertility and its treatment can affect a patient and her spouse or partner medically, financially, socially, emotionally and psychologically. Feelings of anxiousness, depression, isolation, and helplessness are not uncommon among patients undergoing infertility treatment. Strained and stressful relations with spouses, partners and other loved ones are not uncommon as treatment gets underway and progresses.

Our health care team is available to address the emotional, as well as physical symptoms that can accompany infertility. In addition to working with our health care team to minimize the emotional impacts
of infertility treatments, patients may also consider working with mental health professionals who are specially trained in the area of infertility care.

While it is normal to experience emotional ups and downs when pursuing infertility treatment, it is important to recognize when these feelings are of a severe nature. If you experience any of the following symptoms over a prolonged period of time, you may benefit from working with a mental health professional:

- Loss of interest in usual activities
- Depression that doesn't lift
- Strained interpersonal relationships (with partner, family, friends and/or colleagues)
- Difficulty thinking of anything other than your infertility
- High levels of anxiety.
- Diminished ability to accomplish tasks
- Difficulty with concentration
- Change in your sleep patterns (difficulty falling asleep or staying asleep, early morning awakening, sleeping more than usual for you)
- Change in your appetite or weight (increase or decrease)
- Increased use of drugs or alcohol
- Thoughts about death or suicide
- Social isolation
- Persistent feelings of pessimism, guilt, or worthlessness
- Persistent feelings of bitterness or anger

Our health care team can assist you in locating a qualified mental health professional who is familiar with the emotional experience of infertility, or you can contact a national support group such as RESOLVE, (www.resolve.org, Tel. 1-888-623-0744) or The American Fertility Association (AFA), (www.theafa.org, Tel: 1-888-917-3777).

**F. Alternatives to IVF**

There are alternatives to IVF treatment including gamete Intrafallopian transfer (GIFT), zygote intrafallopian transfer (ZIFT) or tubal embryo transfer (TET) where eggs and sperm, fertilized eggs or developing embryos, respectively, are placed into the fallopian tube(s). Using donor sperm, donor eggs, adoption, or not pursuing treatment are also options. Gametes (sperm and/or eggs), instead of embryos may be frozen for future attempts at pregnancy in an effort to avoid potential future legal or ethical issues relating to disposition of any cryopreserved embryos. Sperm freezing, but not egg freezing, has been an established procedure for many decades. Egg freezing is considered an experimental procedure at this time.

**G. Reporting Outcomes**

The 1992 Fertility Clinic Success Rate and Certification Act requires the Centers for Disease Control and Prevention (CDC) to collect cycle-specific data as well as pregnancy outcome on all assisted reproductive technology cycles performed in the United States each year and requires them to report success rates using these data. Consequently, data from my/our IVF procedure will be provided to the CDC, and to the Society of Assisted Reproductive Technologies (SART) of the American Society of Reproductive Medicine (ASRM) (if my/our clinic is a member of this organization). The CDC may request additional information from the treatment center or contact them/us directly for additional follow-up. Additionally, my/our information may be used and disclosed in accordance with HIPAA guidelines in order to perform research or quality control. All information used for research will be de-identified prior to publication. De-identification is a process intended to prevent the data associated with my/our treatment being used to identify me/us as individuals.
H. References

General IVF overviews available on the internet

http://www.sart.org/

http://www.cdc.gov/art/

http://www.resolve.org/site/PageServer

Number of Embryos to Transfer

Culturing Embryos to the Blastocyst Stage

Intracytoplasmic Sperm Injection

In Vitro Maturation

Embryo Hatching

Ovarian Hyperstimulation

Risks of Pregnancy

Risks to Offspring
I. Disposition of Embryos Statement

Because of the possibility of you and/or your partner’s separation, divorce, death or incapacitation after embryos have been produced, it is important to decide on the disposition of any embryos (fresh or cryopreserved) that remain in the laboratory in these situations. Since this is a rapidly evolving field, both medically and legally, the clinic cannot guarantee what the available or acceptable avenues for disposition will be at any future date.

Currently, the alternatives are:
1. Discarding the cryopreserved embryo(s)
2. Donating the cryopreserved embryo(s) for approved research studies.
3. Donating the cryopreserved embryos to another couple in order to attempt pregnancy. (In this case, you may be required to undergo additional infectious disease testing and screening due to Federal or State requirements.)
4. Use by one partner with the contemporaneous permission of the other for that use.

This agreement provides several choices for disposition of embryos in these circumstances (death of the patient or the patient’s spouse or partner, separation or divorce of the patient and her spouse/partner, successful completion of IVF treatment, decision to discontinue IVF treatment, and by failure to pay fees for frozen storage).

I/We agree that in the absence of a more recent written and witnessed consent form, Delaware Valley Institute of Fertility & Genetics is authorized to act on our choices indicated below, so far as it is practical.

I/We also agree that in the event that either our chosen dispositional choices are not available or we fail to preserve any choices made herein, whether through nonpayment of storage fees or otherwise, Delaware Valley Institute of Fertility & Genetics is authorized to discard and destroy our embryos.

Note:

- Embryos cannot be used to produce pregnancy against the wishes of the partner. For example, in the event of a separation or divorce, embryos cannot be used to create a pregnancy without the express, written consent of both parties, even if donor gametes were used to create the embryos.

- Embryo donation to achieve a pregnancy is regulated by the FDA (U.S. Food and Drug Administration) as well as state laws, as donated tissue; certain screening and testing of the persons providing the sperm and eggs are required before donation can occur.

- You are free to revise the choices you indicate here at any time by completing another form and having it notarized.

- Your wills should also include your wishes on disposition of the embryos and be consistent with this consent form. Any discrepancies will need to be resolved by court decree.

- Please check the appropriate box in each section to delineate your wishes and initial the bottom of each page.
Death of Patient

In the event the patient dies prior to use of all the embryos, we agree that the embryos should be disposed of in the following manner (check only one box):

D Award to patient’s spouse or partner, which gives complete control for any purpose, including implantation, donation for research, or destruction. This may entail maintaining the embryos in storage, and the fees and other payments due the clinic for these cryopreservation services.

D Donate to another couple or individual for reproductive purposes. This may entail maintaining the embryos in storage, and the fees and other payments due Delaware Valley Institute of Fertility & Genetics for these cryopreservation services. If you wish, you may designate a couple or individual to receive the embryos. In the event the designated couple or individual is unable or unwilling to accept the embryos, Delaware Valley Institute of Fertility & Genetics will control the donation.

Please donate to:
Name ______________________________
Address ______________________________
Telephone ______________________________
Email ______________________________

Special note for embryos created with gamete donors: If your embryos were formed using gametes (eggs or sperm) from a known third party donor, your instruction to donate these embryos to another couple or individual must be consistent with and in accordance with any and all prior agreements made with the gamete donor(s).

D Award for research purposes, including but not limited to embryonic stem cell research, which may result in the destruction of the embryos but will not result in the birth of a child.

D Destroy the embryos.

D Other disposition (please specify): ______________________________

Default Disposition: I/We understand and agree that in the event none of our elected choices are available, as determined by Delaware Valley Institute of Fertility & Genetics, Delaware Valley Institute of Fertility & Genetics is authorized, without further notice to us, to destroy and discard our embryos.

Death of Spouse or Partner

In the event the patient’s spouse or partner dies prior to use of all the embryos, we agree that the embryos should be disposed of in the following manner (check one box only):

D Award to patient, which gives complete control for any purpose, including implantation, donation for research, or destruction. This may entail maintaining the embryos in storage, and the fees and other payments due Delaware Valley Institute of Fertility & Genetics for these cryopreservation services.

D Donate to another couple or individual for reproductive purposes. This may entail maintaining the embryos in storage, and the fees and other payments due Delaware Valley Institute of Fertility & Genetics for these cryopreservation services. If you wish, you may designate a couple or individual to receive the embryos. In the event the designated couple or individual is unable or unwilling to accept the embryos, Delaware Valley Institute of Fertility & Genetics will control the donation.
Informed Consent for ART

Please donate to:  
Name: ____________________________
Address: ____________________________
Telephone: ____________________________
Email: ____________________________

Special note for embryos created with gamete donors: If your embryos were formed using gametes (eggs or sperm) from a known third party donor, your instruction to donate these embryos to another couple or individual must be consistent with and in accordance with any and all prior agreements made with the gamete donor(s).

D Award for research purposes, including but not limited to embryonic stem cell research, which may result in the destruction of the embryos but will not result in the birth of a child.

D Destroy the embryos.

D Other disposition (please specify): ____________________________

Default Disposition: I/We understand and agree that in the event none of our elected choices are available, as determined by Delaware Valley Institute of Fertility & Genetics, Delaware Valley Institute of Fertility & Genetics is authorized, without further notice to us, to destroy and discard our embryos.

Simultaneous Death of Patient and Spouse or Partner

In the event the patient and her spouse or partner die at the same time, prior to use of all the embryos, we agree that the embryos should be disposed of in the following manner (check one box only):

D Donate to another couple or individual for reproductive purposes. This may entail maintaining the embryos in storage, and the fees and other payments due Delaware Valley Institute of Fertility & Genetics for these cryopreservation services. If you wish, you may designate a couple or individual to receive the embryos. In the event the designated couple or individual is unable or unwilling to accept the embryos, Delaware Valley Institute of Fertility & Genetics will control the donation.

Please donate to:  
Name: ____________________________
Address: ____________________________
Telephone: ____________________________
Email: ____________________________

Special note for embryos created with gamete donors: If your embryos were formed using gametes (eggs or sperm) from a known third party donor, your instruction to donate these embryos to another couple or individual must be consistent with and in accordance with any and all prior agreements made with the gamete donor(s).

D Award for research purposes, including but not limited to embryonic stem cell research, which may result in the destruction of the embryos but will not result in the birth of a child.

D Destroy the embryos.

D Other disposition (please specify): ____________________________

Initials: ____________________________
**Default Disposition**

I/we understand and agree that in the event none of our elected choices are available, as determined by Delaware Valley Institute of Fertility & Genetics, Delaware Valley Institute of Fertility & Genetics is authorized, without further notice to us, to destroy and discard our embryos.

**Divorce or Dissolution of Relationship**

In the event the patient and her spouse are divorced or the patient and her partner dissolve their relationship, we agree that the embryos should be disposed of in the following manner (check one box only):

- **D** A court decree and/or settlement agreement will be presented to Delaware Valley Institute of Fertility & Genetics directing use to achieve a pregnancy in one of us or donation to another couple for that purpose.
- **D** Award for research purposes, including but not limited to embryonic stem cell research, which may result in the destruction of the embryos but will not result in the birth of a child.
- **D** Destroy the embryos.

**Default Disposition**

I/we understand and agree that in the event none of our elected choices are available, as determined by Delaware Valley Institute of Fertility & Genetics, Delaware Valley Institute of Fertility & Genetics is authorized, without further notice to us, to destroy and discard our embryos.

**Nonpayment of Cryopreservation Storage Fees**

Maintaining embryo(s) in a frozen state is labor intensive and expensive. There are fees associated with freezing and maintaining cryopreserved embryo(s). Patients/couples who have frozen embryo(s) must remain in contact with Delaware Valley Institute of Fertility & Genetics on an annual basis in order to inform us of their wishes as well as to pay fees associated with the storage of their embryo(s). In situations where there is no contact with Delaware Valley Institute of Fertility & Genetics for a period of **THREE** years or fees associated with embryo storage have not been paid for a period of **THREE** years and Delaware Valley Institute of Fertility & Genetics is unable to contact the patient after reasonable efforts have been made, the embryo(s) may be destroyed by Delaware Valley Institute of Fertility & Genetics in accordance with normal laboratory procedures and applicable law. Reasonable efforts to reach the patient include:

- Annual notification of continued storage of embryos at last known address for **THREE** years,
- Annual bill for continued storage of embryos at last known address (Year One),
- If no payment after one year, patient sent to collections,
- Annual bill for continued storage of embryos at last known address (Year Two)
- Annual bill for continued storage of embryos by registered mail at last known address (Year Three),

If I/we fail to pay the overdue storage fees within 30 days from the date of said mailings, such failure to pay constitutes my/our express authorization to Delaware Valley Institute of Fertility & Genetics to follow the disposition instructions we have elected below without further communications to or from us (check one box only):

- **D** Award for research purposes, including but not limited to embryonic stem cell research, which may result in the destruction of the frozen embryos but will not result in the birth of a child.
- **D** Destroy the frozen embryos.

**Default Disposition**
I/We understand and agree that in the event none of our elected choices are available, as determined by Delaware Valley Institute of Fertility & Genetics, Delaware Valley Institute of Fertility & Genetics is authorized, without further notice to us, to destroy and discard our frozen embryos.

**Time-Limited Storage of Embryos**

The Clinic will only maintain cryopreserved embryos for a period of **FIVE** years. After that time, we elect (check one box only):

- **D** Award for research purposes, including but not limited to embryonic stem cell research, which may result in the destruction of the frozen embryos but will not result in the birth of a child.
- **D** Destroy the frozen embryos.
- **D** Transfer to a storage facility at our expense.

**Default Disposition**

I/We understand and agree that in the event none of our elected choices are available, as determined by Delaware Valley Institute of Fertility & Genetics, Delaware Valley Institute of Fertility & Genetics is authorized, without further notice to us, to destroy and discard our frozen embryos.

**Age-Limited Storage of Embryos**

I/We understand that Delaware Valley Institute of Fertility & Genetics will not transfer embryos to produce a pregnancy after I reach age 48 years of age (DATE / / ) [Please note the medical clearance requirement on page 3]. After this age, I/we elect (check one box only):

- **D** A court decree and/or settlement agreement will be presented directing use to achieve a pregnancy in the one of us that has not reached this age limit.
- **D** Award for research purposes, including but not limited to embryonic stem cell research, which may result in the destruction of the frozen embryos but will not result in the birth of a child.
- **D** Destroy the frozen embryos.
- **D** Transfer to a storage facility at our expense.
- **D** Donate the cryopreserved embryos to another couple for reproductive purposes.

**Default Disposition**

I/We understand and agree that in the event none of our elected choices are available, as determined by Delaware Valley Institute of Fertility & Genetics, Delaware Valley Institute of Fertility & Genetics is authorized, without further notice to us, to destroy and discard our frozen embryos.
Donation of Frozen Embryos For Research Purposes

If you selected the option “award for research purposes” under any of the preceding circumstances, as a donor of human embryos to research, including but not limited to stem cell research, you should be aware of the following:

- Donating embryo(s) for research or to another couple may not be possible or may be restricted by law. While efforts will be made to abide by your wishes, no guarantees can be given that embryo(s) will be used for research or donated to another couple. In these instances, if after FIVE years no recipient or research project can be found, or your embryos are not eligible, your embryo(s) will be destroyed and discarded by the lab in accordance with laboratory procedures and applicable laws.
- The embryos may be used to derive human pluripotent stem cells for research and the cells may be used, at some future time, for human transplantation research.
- All identifiers associated with the embryos will be removed prior to the derivation of human pluripotent stem cells.
- Donors to research will not receive any information about subsequent testing on the embryo or the derived human pluripotent cells.
- Derived cells or cell lines, with all identifiers removed, may be kept for many years.
- It is possible the donated material may have commercial potential, but the donor will receive no financial or other benefit from any future commercial development.
- Human pluripotent stem cell research is not intended to provide direct medical benefit to the embryo donor.
- Donated embryos will not be transferred to a woman’s uterus, nor will the embryos survive the human pluripotent stem cell derivation process. Embryos will be handled respectfully, as is appropriate for all human tissue used in research.
- If the donated embryos were formed with gametes (eggs or sperm) from someone other than the patient and her spouse or partner (those who are signators to this document), the gamete donor(s) may be required to provide a signed, written consent for use of the resulting embryos for research purposes.
Legal Considerations and Legal Counsel

The law regarding embryo cryopreservation, subsequent thaw and use, and parent-child status of any resulting child(ren) is, or may be, unsettled in the state in which either the patient, spouse, partner, or any donor currently or in the future lives, or New Jersey in which Delaware Valley Institute of Fertility & Genetics is located. We acknowledge that Delaware Valley Institute of Fertility & Genetics has not given us legal advice, that we are not relying on Delaware Valley Institute of Fertility & Genetics to give us any legal advice, and that we have been informed that we may wish to consult a lawyer who is experienced in the areas of reproductive law and embryo cryopreservation and disposition if we have any questions or concerns about the present or future status of our embryos, our individual or joint access to them, our individual or joint parental status as to any resulting child, or about any other aspect of this consent and agreement.

Our signatures below certify the disposition selections we have made above. We understand that we can change our selections in the future, but need mutual and written agreement as outlined above. We also understand that in the event that none of our elected choices is available, Delaware Valley Institute of Fertility & Genetics is authorized, without further notice from us, to destroy and discard our frozen embryos.

X
Patient Signature

Patient Name

Date

Date of Birth

X
Spouse / Partner Signature

Spouse / Partner Name

Date

Date of Birth

Initials: /